X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SUVEN LIFE ALEMBIC PHARMA/
SUVEN LIFE
 
P/E (TTM) x 28.9 19.3 149.9% View Chart
P/BV x 6.6 3.6 184.3% View Chart
Dividend Yield % 0.7 1.0 68.2%  

Financials

 ALEMBIC PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
SUVEN LIFE
Mar-16
ALEMBIC PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs792339 233.9%   
Low Rs443144 306.8%   
Sales per share (Unadj.) Rs167.039.2 425.6%  
Earnings per share (Unadj.) Rs38.27.5 511.5%  
Cash flow per share (Unadj.) Rs42.08.8 478.5%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.8 78.2%  
Book value per share (Unadj.) Rs84.949.0 173.3%  
Shares outstanding (eoy) m188.52127.28 148.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.76.2 60.1%   
Avg P/E ratio x16.232.4 50.0%  
P/CF ratio (eoy) x14.727.5 53.4%  
Price / Book Value ratio x7.34.9 147.6%  
Dividend payout %10.526.8 39.1%   
Avg Mkt Cap Rs m116,38330,732 378.7%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m4,214416 1,012.0%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m31,4874,995 630.3%  
Other income Rs m55194 28.5%   
Total revenues Rs m31,5425,189 607.9%   
Gross profit Rs m10,0601,233 816.1%  
Depreciation Rs m722167 431.9%   
Interest Rs m3754 67.9%   
Profit before tax Rs m9,3561,205 776.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160255 847.1%   
Profit after tax Rs m7,194950 757.5%  
Gross profit margin %31.924.7 129.5%  
Effective tax rate %23.121.2 109.1%   
Net profit margin %22.819.0 120.2%  
BALANCE SHEET DATA
Current assets Rs m15,0664,986 302.2%   
Current liabilities Rs m7,6741,042 736.3%   
Net working cap to sales %23.579.0 29.7%  
Current ratio x2.04.8 41.0%  
Inventory Days Days6761 109.8%  
Debtors Days Days4139 103.8%  
Net fixed assets Rs m8,2373,126 263.6%   
Share capital Rs m377127 296.2%   
"Free" reserves Rs m15,4163,717 414.7%   
Net worth Rs m16,0056,236 256.6%   
Long term debt Rs m0432 0.0%   
Total assets Rs m24,5948,079 304.4%  
Interest coverage x255.223.2 1,098.9%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.6 207.1%   
Return on assets %29.412.4 236.6%  
Return on equity %44.915.2 295.2%  
Return on capital %58.718.9 310.8%  
Exports to sales %55.787.5 63.7%   
Imports to sales %10.412.2 85.3%   
Exports (fob) Rs m17,5514,371 401.6%   
Imports (cif) Rs m3,283611 537.5%   
Fx inflow Rs m17,8114,666 381.7%   
Fx outflow Rs m5,318942 564.5%   
Net fx Rs m12,4933,724 335.4%   
CASH FLOW
From Operations Rs m9,304922 1,009.1%  
From Investments Rs m-3,105-619 501.3%  
From Financial Activity Rs m-1,959-698 280.5%  
Net Cashflow Rs m4,240-396 -1,071.5%  

Share Holding

Indian Promoters % 74.1 63.4 116.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.5 38.1%  
Shareholders   49,328 37,287 132.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 21, 2018 01:09 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - UNICHEM LAB COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS